In a phase II trial involving 96 patients with advanced CRC, a vaccination mixture of five HLA-A*2404-restricted peptides (RNF43, KOC1, TOMM34, VEGFR1, VEGFR2) was proven safe while simultaneously applied with oxaliplatin-based chemotherapy (32). Here, FLT1 is linked to colorectal carcinoma.